Biogen Inc. ( BIIB) – Erosion of TECFIDERA revenue created negative impact on company performance

in , on February 11, 2021

The company entered into a collaboration with Atalanta Therapeutics. As part of this collaboration, Atalanta will utilize its proprietary branched siRNA platform to develop potential treatments for multiple CMS targets, including HTT for the treatment of Huntington’s disease.

Highlights 

Valuation

– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

 Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Developments
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

CrispIdea Coverage

No of Pages : 38

Release Information

  • Released
    :

    February 11, 2021

  • Last Updated
    :

    February 23, 2021